CONSHOHOCKEN, Pa., - The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and ePharmaSolutions today announced their partnership to build and deliver online learning courses to clinicians working in psoriasis (PsO) and psoriatic arthritis (PsA) research and development.
Via the ePharmaSolutions eClinical platform, GRAPPA is able to offer training designed to standardize the use of rating scales for PsO and PsA, improving endpoint reliability in research trials in a cost-effective manner. "We are very excited to be collaborating with ePharmaSolutions," says Pam Love, Executive Director at GRAPPA. "Our members are enthusiastic about sharing their expertise in psoriasis and psoriatic arthritis with the research industry, and the ePharmaSolutions platform enables us to deliver this knowledge efficiently to clinicians around the world."
According to Dr. Kristina Callis Duffin, M.D., Assistant Professor of Dermatology at the University of Utah, GRAPPA Board member and leader of this initiative, "With growing interest from regulators about training of psoriasis assessments, standardizing the approach to their use and training clinicians about them is vital to clinical research success."
"ePharmaSolutions is proud to be a partner with GRAPPA and look forward to developing solutions that help improve endpoint reliability studies with subjective endpoints," states Lance Converse, Founder & CEO of ePharmaSolutions. "Offering cloud-based online solutions that can be accessed easily and globally will extend our expertise deeply into dermatology and rheumatology for endpoint reliability certifications" added Converse.